533 related articles for article (PubMed ID: 18834945)
1. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
Holbrook M; Malik M; Shah RR; Valentin JP
J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
[TBL] [Abstract][Full Text] [Related]
2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
3. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
4. Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.
Malik M
Drug Saf; 2016 Jul; 39(7):647-59. PubMed ID: 26968542
[TBL] [Abstract][Full Text] [Related]
5. Shortening of the electromechanical window in the ketamine/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development.
Morissette P; Regan C; Fitzgerald K; Gerenser P; Travis J; Wang S; Fanelli P; Sannajust F
J Pharmacol Toxicol Methods; 2016; 81():171-82. PubMed ID: 27377419
[TBL] [Abstract][Full Text] [Related]
6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
7. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
Othong R; Devlin JJ; Kazzi ZN
Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
[TBL] [Abstract][Full Text] [Related]
8. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications.
Giorgi MA; Bolaños R; Gonzalez CD; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):54-7. PubMed ID: 20210719
[TBL] [Abstract][Full Text] [Related]
9. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
10. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
11. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
12. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
[TBL] [Abstract][Full Text] [Related]
13. An overview of QT interval assessment in safety pharmacology.
Lacroix P; Picard S
Curr Protoc Pharmacol; 2006 Jul; Chapter 10():Unit10.7. PubMed ID: 22294169
[TBL] [Abstract][Full Text] [Related]
14. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
Markert M; Shen R; Trautmann T; Guth B
J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
[TBL] [Abstract][Full Text] [Related]
15. QT prolongation and safety in the Indian population.
Dabhi J; Mehta A
Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
[TBL] [Abstract][Full Text] [Related]
16. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
17. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
18. QT and TdP. QT: an unreliable predictor of proarrhythmia.
Hondeghem LM
Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
[TBL] [Abstract][Full Text] [Related]
19. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
20. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
